Design Therapeutics (DSGN)
(Delayed Data from NSDQ)
$4.75 USD
+0.04 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $4.76 +0.01 (0.21%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
DSGN 4.75 +0.04(0.85%)
Will DSGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DSGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DSGN
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
DSGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DSGN
Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress
RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC? Portfolio
Design Therapeutics expects cash to fund expenses into 2029
Design Therapeutics reports Q2 EPS (21c), consensus (23c)